NextCure Management
Management criteria checks 3/4
NextCure's CEO is Michael Richman, appointed in Oct 2015, has a tenure of 8.42 years. total yearly compensation is $1.72M, comprised of 31.9% salary and 68.1% bonuses, including company stock and options. directly owns 1.42% of the company’s shares, worth $788.69K. The average tenure of the management team and the board of directors is 3.2 years and 4.9 years respectively.
Key information
Michael Richman
Chief executive officer
US$1.7m
Total compensation
CEO salary percentage | 31.9% |
CEO tenure | 8.4yrs |
CEO ownership | 1.4% |
Management average tenure | 3.2yrs |
Board average tenure | 4.9yrs |
Recent management updates
Recent updates
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Mar 23We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Dec 09Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?
Aug 23Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
May 10We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Nov 22Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)
Aug 09NextCure GAAP EPS of -$0.59
Aug 04We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate
May 02NextCure: Large Upside With Downside Protected By Cash Pile
Sep 29NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow
May 10NextCure EPS misses by $0.01
May 06Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like
Feb 12NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares
Jan 08NextCure provides update on NC318 clinical program
Dec 17CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$63m |
Sep 30 2023 | n/a | n/a | -US$66m |
Jun 30 2023 | n/a | n/a | -US$70m |
Mar 31 2023 | n/a | n/a | -US$70m |
Dec 31 2022 | US$2m | US$549k | -US$75m |
Sep 30 2022 | n/a | n/a | -US$74m |
Jun 30 2022 | n/a | n/a | -US$73m |
Mar 31 2022 | n/a | n/a | -US$73m |
Dec 31 2021 | US$3m | US$529k | -US$69m |
Sep 30 2021 | n/a | n/a | -US$68m |
Jun 30 2021 | n/a | n/a | -US$66m |
Mar 31 2021 | n/a | n/a | -US$63m |
Dec 31 2020 | US$6m | US$491k | -US$37m |
Sep 30 2020 | n/a | n/a | -US$32m |
Jun 30 2020 | n/a | n/a | -US$24m |
Mar 31 2020 | n/a | n/a | -US$18m |
Dec 31 2019 | US$626k | US$419k | -US$34m |
Sep 30 2019 | n/a | n/a | -US$30m |
Jun 30 2019 | n/a | n/a | -US$27m |
Mar 31 2019 | n/a | n/a | -US$24m |
Dec 31 2018 | US$3m | US$383k | -US$23m |
Compensation vs Market: Michael's total compensation ($USD1.72M) is above average for companies of similar size in the US market ($USD661.05K).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Richman (62 yo)
8.4yrs
Tenure
US$1,724,186
Compensation
Mr. Michael S. Richman, MSBA, Co-founded NextCure, Inc. since 2015 and has been its Chief Executive Officer, President & Director since July 2015. Mr. Richman served as the Chief Executive Officer and Pres...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 8.4yrs | US$1.72m | 1.42% $ 788.7k | |
Chief Scientific Officer | 5.3yrs | US$990.52k | 0.13% $ 74.3k | |
Chief Medical Officer | 3.2yrs | US$953.32k | 0% $ 0 | |
Co-Founder & Chairman of Scientific Advisory Board | 9.2yrs | no data | no data | |
Chief Financial Officer | 6.2yrs | US$1.01m | no data | |
Chief Operating Officer | 4.4yrs | no data | no data | |
General Counsel | 1.8yrs | no data | no data | |
Vice President of Human Resources | less than a year | no data | no data | |
Senior Vice President of Development & Manufacturing | 2.7yrs | no data | no data | |
Senior Vice President of Business Development | less than a year | no data | no data | |
Senior Vice President of Clinical & Translational Development | less than a year | no data | no data |
3.2yrs
Average Tenure
62.5yo
Average Age
Experienced Management: NXTC's management team is considered experienced (3.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 8.4yrs | US$1.72m | 1.42% $ 788.7k | |
Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 8.3yrs | US$94.17k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Chairman of the Board | 8.3yrs | US$122.67k | 0.22% $ 123.9k | |
Independent Director | 4.9yrs | US$101.17k | 0% $ 0 | |
Independent Director | 8.3yrs | US$96.17k | 0% $ 0 | |
Independent Director | 2.4yrs | US$91.17k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 3.5yrs | US$91.17k | 0% $ 0 | |
Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
Independent Director | 2.4yrs | US$90.17k | 0% $ 0 |
4.9yrs
Average Tenure
64yo
Average Age
Experienced Board: NXTC's board of directors are considered experienced (4.9 years average tenure).